title: Drug-eluting stents: potential applications for peripheral arterial occlusive disease.
abstract: Many different approaches have been evaluated to prevent restenosis in stents after vascular implantation. Currently, drug-eluting stents are extremely promising in suppressing neointimal hyperplasia. Various animal studies and randomized trials in humans have shown excellent results in terms of safety and efficacy during intermediate-term follow-up. This article will give an overview of experimental and clinical data of the different agents in published and ongoing trials.
authors.affiliation: Department of Diagnostic Radiology, University of Tuebingen, Germany. stephan.duda@med.uni-tuebingen.de
authors.forename: Stephan H
authors.initials: SH
authors.lastname: Duda
authors.forename: Tudor C
authors.initials: TC
authors.lastname: Poerner
authors.forename: Benjamin
authors.initials: B
authors.lastname: Wiesinger
authors.forename: John H
authors.initials: JH
authors.lastname: Rundback
authors.forename: Gunnar
authors.initials: G
authors.lastname: Tepe
authors.forename: Jakub
authors.initials: J
authors.lastname: Wiskirchen
authors.forename: Karl K
authors.initials: KK
authors.lastname: Haase
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001157:Arterial Occlusive Diseases / Q000517:prevention & control*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003907:Dexamethasone / Q000008:administration & dosage; D016503:Drug Delivery Systems; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D011474:Prosthesis Design; D012008:Recurrence; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents; D014654:Vascular Patency
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003907:Dexamethasone; D017239:Paclitaxel; D020123:Sirolimus